1. Khalid “Kal” Mentak, PhD
Catalyst Technology Innovation Group
Palo Alto, CA
Empowering IP from Idea to Market
The Glakolens Case

2. Historical Perspective
Companies in the Biotech and Healthcare segment use Universities as fundamental research centers through sponsored research programs
IP is assigned to sponsors through licensing agreements
In most cases IP is not managed properly based on the lack of incentives for value creation

3. The landscape has changed
Universities are taking a proactive approach to monetize IP independently of sponsors
Incubators, accelerators, and investment centers are playing an increasing role in leveraging academic IP
Better IP quality and management through outside due diligence and independent investors

4. The New Value Creation Model
Bring investment, regulatory, and entrepreneurial expertise to universities
Educate students and faculty members on how to integrate value creation into creating innovative IP
Highlight the role of strong and well managed IP in improving lives and driving innovation

5. Bringing VCs, faculty members, and entrepreneurs together to drive healthcare innovation
Educational curriculum with intensive interactions with the VC community in Silicon Valley
A strong focus on creating and managing IP within the academic environment

6. Value-Driven IP creation Model
Capital
Clinical Need
Project Generation
IP Creation
Strategy
Management
Business
Advisory Group
• Execution Plan
• Milestones & Goals
• First-in-Man
Regulatory
Advisory Group
• Clinical Need Assessment
• MKT Opportunity Assessment
• Project Scope Analysis

7. The Glakolens Case Unmet Clinical Need
Glaucoma is a chronic disease with no cure
70M people worldwide have glaucoma - €5B Market
The 2nd leading cause of blindness globally
It develops due to increased intraocular pressure (IOP)
The ability to monitor IOP over an extended period of time is critical to delivering efficient therapy
No viable product on the market

8. The Glakolens Case The Solution
Development and market introduction of the first non- invasive wireless, contact lens- based IOP monitoring system capable of collecting data over prolonged periods of time

9. The Glakolens Case The Technology
Based on a low cost and easy to manufacture passive biosensor.
Accurately monitors fluctuations in IOP by measuring changes in the geometry of a sensor placed on the cornea.
First non-invasive, wireless, and continuous IOP monitoring system

10. The Glakolens Case Investment-driven IP Assessment
Value-driven evaluation
Deep understanding of the glaucoma market
KOL assessment
Market acceptance
Regulatory path
Sales strategy
Exit strategy

11. The Glakolens Case Conventional IP Assessment
Patentability
FTO
Infringement
Patent coverage based on business strategy

12. Leveraging IP to Get from Idea to Market
Timeframe
Milestone
Year 1
Produce Prototype
File for International Patent
Year 2
Produce Functional Model
Obtain Issued Patents
Initiate Validation
Year 3
Perform Full Validation
Expand IP
Strategic positioning for potential exit or licensing deal
Pitch the product to various strategics in ophthalmology, optometry, and telemedicine
Year 4
Obtain CE Mark
Perform Clinical Validation
Launch in Selected Markets